

## ORYZON shareholders approve listing to the Spanish Continuous Market

- **Company to submit prospectus in Q4-2015**
- **Solventis AV investment banking will coordinate the IPO process**

**BARCELONA / CAMBRIDGE, MA, September 16, 2015** - The General Meeting of Shareholders of Oryzon Genomics, a clinical stage biopharmaceutical company focused on Epigenetics to develop therapies in oncology and neurodegenerative diseases, agreed to publicly trade 100% of the company's shares in the Spanish Main Market.

Oryzon will carry out the listing process by submitting the prospectus to the National Securities Market Commission (CNMV in Spain) in Q4-2015 followed by trading on the Madrid Stock Exchange upon standard regulatory process approvals expected to 2016. The firm has engaged Solventis AV to coordinate the investment banking and registration listing process.

Oryzon achieved a net profit of 6.6 million Euros in 2014, with revenues of 13.1 million Euros. The success of the company during the past year was driven by its agreement with Roche in April 2014, in which the company licensed the rights of its molecule ORY-1001, a LSD1 inhibitor, to the Swiss multinational. Under terms of the multimillion dollar agreement, Oryzon could receive +US\$500 million in milestones plus tiered sales royalties. Under this agreement, the company received US\$21 million including US\$4 million in Q3-2015, upon reaching a new milestone in the development of its drug against acute myeloid leukemia (AML), which is being tested in a human phase IIA clinical trial.

Also, Oryzon is advancing its leading research on epigenetic treatments for neurodegenerative diseases, and its forerunner asset, ORY-2001 a dual LSD1-MAOB inhibitor, intended to treat neurodegenerative diseases such as Alzheimer's Disease is finalizing the preclinical studies. This molecule, which manages to stop the cognitive decline in animal models, will begin human clinical phase I trials in early 2016. ORY-2001 can also be useful in other diseases of the nervous system such as Parkinson's disease and other dementia related diseases, such as Huntington's disease.

The company will pursue its US plans from its office in Cambridge, Mass. and plans to float in Nasdaq by a dual listing in the midterm. The company president, Carlos Buesa, explained that this operation is "a new step in the commitment to the growth and

internationalization of the company and will serve to prepare us to gain dimension, to accelerate the pace of our clinical programs and for the eventual listing in the Nasdaq Exchange, the medium term objective of Oryzon."

On December 31, 2014, 32.828% of the shares of Oryzon were held by the founding partners, Carlos Buesa (16,414%) and Tamara Maes (16,414%), while the equity fund Najeti holds 30.779%. In addition, other shareholders with a significant ownership of the company include the Costex Family Office (5,986%), Sant Bernat SCR RC Corporation SA (4.592%), Josep María Echarri Torres (4,504%) and Grupo Ferrer Internacional (3,217%). The core of the company has committed to a process of lock up, by which Oryzon's founders, Carlos Buesa and Tamara Maes, are obligated to not to sell their shares on the market within 12 months of listing on the Spanish Continuous Market. In the case of the Najeti fund and José María Echarri, the lockup period will be six months.

#### **About Oryzon**

Founded in 2000 in Barcelona, Spain, Oryzon ([www.oryzon.com](http://www.oryzon.com)) is a privately held, clinical stage biopharmaceutical company considered as the European champion in Epigenetics with one of the strongest portfolios in the field. Its LSD1 program is currently covered by 19 patent families and has rendered one compound in clinical trials and another one is anticipated to enter clinical trials in early 2016. In addition, Oryzon has ongoing programs for developing inhibitors against other histone demethylases and histone methyltransferases. The company has also a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. The opening of Oryzon's U.S. operations in Cambridge, Massachusetts, was announced in October 2014.

**For more information, please contact:**

**ATREVIA**

+34 91 564 07 25

**Ana Melgar** / [amelgar@atrevia.com](mailto:amelgar@atrevia.com)

**Patricia Cobo** / [pcobo@atrevia.com](mailto:pcobo@atrevia.com)